Dalfampridine

达伐吡啶

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NameDalfampridine
Drug Alias NameDalfampridine-SR氨基吡啶氨吡啶Dalfampridine-QD达方吡啶 +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel blockersVoltage-gated potassium channel blockers
TargetsPotassium channelVoltage-gated potassium channel
Therapy Area/IndicationsIschemic StrokeMemory, Short-TermCrush Injuries +[21] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2010/01/22
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAcorda Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of BaselMerz Therapeutics GmbHMerz Pharmaceuticals LLC +[8] 
Inactive CompaniesAcorda TherapeuticsOregon Health And Science UniversityThe Brigham and Women's Hospital +[12] 
Active IndicationsMemory, Short-TermCrush InjuriesPeripheral Nerve Injuries +[6] 
Inactive IndicationsIschemic StrokeFatigueRenal Insufficiency +[15] 

Other Information

ATC CodeN07XX07
Related LinksWikipediaDrugBankKEGG